Adalimumab Products (Humira® , Abrilada™, Amjevita® , Cyltezo® , Hadlima™, Hulio®, Hyrimoz®, Idacio®, Simlandi® , Yuflyma®, Yusimry™, adalimumab)

Adalimumab products are covered for the listed FDA-approved and specified compendial indications (e.g., ankylosing spondylitis, Crohn’s, UC, RA, JIA, psoriasis, hidradenitis suppurativa, uveitis, Behçet’s, pyoderma gangrenosum, sarcoidosis, scleritis, and other spondyloarthritis); biosimilars of the requested biologic generally do not count toward required prior-therapy trials. Coverage requires meeting indication-specific age limits, appropriate specialist prescribing/consultation, documented trials of specified prior therapies (or documented contraindications/surgical alternatives), adherence to dosing/administration rules, and for reauthorization objective or symptomatic clinical improvement per condition-specific measures.

"Ankylosing spondylitis"

Sign up to see full coverage criteria, indications, and limitations.